If approved, Delpor’s naltrexone implant is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses. BRISBANE, CA, April 19, 2022 — Delpor, Inc. (Delpor), [...]
If approved, Delpor’s risperidone implant will be the first once-yearly schizophrenia maintenance therapy. BRISBANE, CA, April 22, 2021 — Delpor, Inc. (Delpor), a clinical-stage biopharmaceutical company that utilizes innovative technologies in order to develop once-yearly [...]
Smith will also be responsible for optimizing customer experience for Delpor’s implant products, as he oversaw over 23k procedures for another implant biotech BRISBANE, CA, March 31, 2021 — Delpor, Inc. (Delpor), a clinical stage [...]
Company to expand the use of its PROZOR implant technology by building on the success with its lead antipsychotic program Upon successful completion of the grant’s initial phase, Delpor may receive additional funding in order [...]